酪氨酸激酶抑制剂治疗时代基于细胞遗传学的慢性髓性白血病急变风险预测
该研究在2326例接受酪氨酸激酶抑制剂(TKI)治疗的慢性髓性白血病(CML)患者中,依据附加染色体异常(ACA)谱评估急变(BP)风险。研究将患者分为中危1、中危2和高危组,中危2和高危组从ACA出现到急变的中位时间分别为19.2个月和1.9个月,高危组5年累积急变概率达67.4%。结论认为ACA出现至急变的时间间隔是BP风险的主要决定因素,高危ACA患者可能受益于及时替代治疗。
要点
- 基于ACA谱将CML患者分为中危1、中危2和高危组,中危2和高危组从ACA出现到急变的中位时间分别为19.2个月和1.9个月。
- 包括无ACA的标准风险组在内,四组5年累积急变概率分别为9.8%、28.0%、41.7%和67.4%。
- 84.4%的急变患者在诊断后5年内发生急变,ACA出现至急变的时间间隔是BP风险的主要决定因素。
核心结论
- ACA出现至急变的时间间隔是CML急变风险和患者结局的主要决定因素。
- TKI治疗通过延长该时间间隔降低了低危ACA或无ACA患者的急变风险,但未改变携带高危ACA的CML的自然病程。
- 研究识别出急变高危患者群体,可能受益于及时的替代治疗以预防急变发生。
研究设计与样本
- 研究为队列研究,纳入2326例接受酪氨酸激酶抑制剂(TKI)治疗的慢性髓性白血病(CML)患者,基于附加染色体异常(ACA)谱评估急变(BP)风险。
主要发现
- 从ACA出现至急变的中位时间在中危1组为未达到、中危2组为19.2个月、高危组为1.9个月。
- 三组间从初始诊断至ACA出现的时间间隔以及急变后生存时间无差异。
- 包括无ACA的标准风险组在内,四组5年累积急变概率分别为9.8%、28.0%、41.7%和67.4%。
- 发生急变的患者中,无论细胞遗传学改变如何,急变前病程相似,84.4%的急变患者在诊断后5年内发生急变。
临床怎么用
- 作者认为,基于ACA谱识别出的急变高危患者可能受益于及时的替代治疗以预防急变发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The high fatality of patients with blast phase (BP) chronic myeloid leukemia (CML) necessitates identification of high-risk (HR) patients to prevent onset of BP. Here, we investigated the risk of BP based on additional chromosomal abnormality (ACA) profiles in a cohort of 2326 CML patients treated with tyrosine kinase inhibitors (TKIs). We examined the time intervals from initial diagnosis to ACA emergence (interval 1), from ACA emergence to onset of BP (interval 2), and survival after onset of BP (interval 3). Based on BP risk associated with each ACA, patients were stratified into intermediate-1, intermediate-2, and HR groups, with a median duration of interval 2 of unreached, 19.2 months, and 1.9 months, respectively. There was no difference in durations of intervals 1 or 3 among 3 groups. Including patients without ACAs who formed the standard-risk group, the overall 5-year cumulative probability of BP was 9.8%, 28.0%, 41.7%, and 67.4% for these 4 groups, respectively. The pre-BP disease course in those who developed BP was similar regardless of cytogenetic alterations, and 84.4% of BP patients developed BP within the first 5 years of diagnosis. In summary, interval 2 is the predominant determinant of BP risk and patient outcome. By prolonging the duration of interval 2, TKI therapy mitigates BP risk associated with low-risk ACAs or no ACAs but does not alter the natural course of CML with HR ACAs. Thus, we have identified a group of patients who have HR of BP and may benefit from timely alternative treatment to prevent onset of BP.
引用
- Gong Z, Medeiros LJ, Cortes JE, et al. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv. 2017. PMID: 29296906. doi:10.1182/bloodadvances.2017011858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。